IM19 CAR-T cells

BIOLOGICAL5 trials

Sponsors

Beijing Immunochina Medical Science & Technology Co., Ltd., Peking University Third Hospital

Conditions

LeukemiaLymphomaLymphoma, Mantle-CellLymphoproliferative DisordersNHLNeoplasmsNeoplasms by Histologic TypeRefractory Systemic Lupus Erythematosus

Early Phase 1

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Beijing Immunochina Medical Science & Technology Co., Ltd.Leukemia

Start: 2022-07-11End: 2024-10-01Target: 9Updated: 2022-07-29

Phase 1

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

RecruitingNCT04440436

Beijing Immunochina Medical Science & Technology Co., Ltd.NHL

Start: 2020-06-04End: 2035-06-04Target: 52Updated: 2020-12-08

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Beijing Immunochina Medical Science & Technology Co., Ltd.Lymphoma, Lymphoma, Mantle-Cell, Lymphoproliferative Disorders +2

Start: 2021-12-31End: 2023-02-28Target: 68Updated: 2021-12-13

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Beijing Immunochina Medical Science & Technology Co., Ltd.Leukemia

Start: 2022-04-01End: 2025-06-01Target: 58Updated: 2022-04-04

Unknown Phase

IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)

RecruitingNCT06513429

Peking University Third HospitalRefractory Systemic Lupus Erythematosus

Start: 2024-07-30End: 2027-12-31Target: 6Updated: 2025-08-17

Related Papers

Next-day manufactured CD19 CAR-T cells exhibit superior persistence compared to conventional CAR-T therapy in R/R B-ALL

Blood2025-11-03